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The median age was 61 years (range 34 -79). Systemic amyloidosis with dominant gastrointestinal involvement was present in 60 (79%) patients. Amyloidosis localized to the gastrointestinal tract without evidence of an associated plasma cell dyscrasia or other organ involvement comprised 16 (21%) patients. Of the 60 systemic cases, 50 (83%) had immunoglobulin light-chain, 5 (8%) familial lysozyme, 3 (5%) wild type transthyretin, and 2 (3%) mutant transthyretin amyloidosis. The most frequent symptoms for all patients were weight loss in 33 (45%) and gastrointestinal bleeding in 27 (36%). Incidental identification of amyloidosis on routine endoscopic surveillance played a role in the diagnosis of 7 patients with systemic immunoglobulin light-chain, and 4 patients with immunoglobulin light-chain localized to the gastrointestinal tract. Amyloid protein subtyping was performed in 12 of the cases of localized disease, and all had lambda light chain disease. Of the 50 patients with systemic immunoglobulin light-chain amyloidosis, 45 patients were treated with anti-plasma cell therapy.
The median survival has not been reached for this group. For the 16 patients with localized gastrointestinal amyloidosis, supportive care was the mainstay of treatment; none received anti plasma cell therapy. All 16 are alive at a median follow-up of 36 months (range 1 -143). loss and bleeding. In localized cases, all that underwent typing were due to λ light chain amyloidosis and none progressed to systemic disease during the period of follow-up. Most patients with systemic disease had immunoglobulin light-chain, and their tolerance of therapy and median survival were excellent. Although a rare manifestation of amyloidosis, staining for amyloid should be considered in patients undergoing gastrointestinal biopsy who have unexplained chronic gastrointestinal symptoms.
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Introduction:
The amyloidoses are a heterogeneous group of diseases, characterized by the misfolding of extracellular proteins, generating insoluble fibrils resulting in disruption of tissue structure and function (1, 2) . Fibrils are comprised of protofilaments, made up of beta-sheet rich polypeptides.
By electron microscopy, amyloid fibrils are ~10 nm in diameter; by polarized light microscopy, the regular structure of the fibril leads to apple green-birefringence following staining with Congo red dye (1) . At least 27 different human proteins have been identified to date as amyloidogenic, causing both systemic and localized disease (3) . Systemic amyloidosis, the most common type of amyloid disease, is characterized by production of amyloidogenic precursor proteins at a site remote from the organs of amyloid deposition. Localized amyloidosis, in comparison, is defined by the production of precursor proteins in the same location as amyloid deposition (4, 5) .
Systemic amyloidosis can be acquired, as in immunoglobulin light chain (AL) amyloidosis caused by an underlying clonal plasma cell dyscrasia (PCD); or hereditary, as most commonly occurs by modification of the transthyretin gene (mutant ATTR). Wild type transthyretin can also form amyloid disease in older patients, in a process termed senile systemic amyloidosis (SSA). Both AL and ATTR amyloidosis are characterized by multi-system disease, typically involving the heart and kidneys in AL, whereas ATTR preferentially affects the heart and nervous system; often with gastrointestinal (GI) symptoms such as diarrhea and weight loss due to autonomic neuropathy (6) . Familial or hereditary amyloidosis encompasses multiple amyloidogenic precursor proteins in addition to ATTR including apolipoprotein AI, apolipoprotein AII, fibrinogen Aα chain, and lysozyme (ALys) (3). ALys is a non-neuropathic hereditary disease that mimics AL amyloidosis, predominantly affecting the GI tract, liver, and 5 kidneys (7). Localized amyloidosis is less common, typically occurring in the respiratory tract, bladder, breast, skin, or GI tract (2, 8) .
GI involvement in AL amyloidosis is defined as the presence of GI symptoms with direct biopsy verification (9) . Although standardized guidelines for diagnosis and staging of non-AL forms of systemic amyloidosis and localized amyloidosis have not been developed, clinicians often define organ involvement as is done for AL amyloidosis. While many patients with systemic AL disease have amyloid deposits in blood vessels from GI tract biopsies, GI tract involvement with both symptoms and biopsy proof of involvement of the intestinal tissue itself is less common. One series examining 445 patients with AL amyloidosis identified GI involvement in 7% of patient (1) .
Commonly reported symptoms of GI amyloidosis include esophageal reflux, constipation, nausea, and abdominal pain. Other symptoms such as diarrhea, weight loss, and early satiety, which are commonly attributed to GI amyloidosis, may be caused by other mechanisms such as autonomic neuropathy, small bowel bacterial overgrowth, or cardiac cachexia (2, 10, 11) . Autonomic neuropathy plays a major role in the GI symptoms described in ATTR amyloidosis, contributing to overall morbidity in disease progression, and may also complicate liver transplantation (12, 13) . GI amyloid deposits identified by endoscopic biopsy occur most often in the duodenum, followed by stomach, colorectum, and esophagus (14) .
Reports of amyloidosis localized to the GI tract are limited to case reports and small patient series (15) .
This retrospective study details clinical characteristics, pathologic findings, risk for progression to systemic amyloidosis, indications for chemotherapy, and associated toxicities as well, as survival in this series of 76 patients.
Design and Methods

Patients
Data were collected retrospectively from January 1, 1998 to December 31, 2011, using the Boston University Amyloid Treatment and Research Program database. A total of 2,334 consecutive patients with all types of amyloidosis were evaluated during this time. Patients with documented GI amyloidosis were included in this series; GI amyloidosis was diagnosed when patients presented with GI symptoms and had biopsy proof of involvement of the GI tract.
Histologically, vascular amyloid deposition only was not considered sufficient for a diagnosis; amyloid deposition had to occur in the extravascular space, e.g. within the muscularis mucosa, submucosal, and muscularis propria, as proof of GI tract involvement. Biopsies from outside institutions were reviewed, with repeat Congo red staining if necessary for confirmation. Patients with evidence of an underlying clonal plasma cell or lymphoplasmacytic disorder and AL amyloidosis were considered as systemic AL type, including patients with co-existent multiple myeloma and Waldenström's macroglobulinemia as well as those with primary AL. Localized amyloidosis was diagnosed when GI amyloid deposition was present without evidence of systemic disease or an associated plasma cell dyscrasia. Immunohistochemical staining, mass spectrometry, or immunogold electron microscopy was used to type the amyloid deposits. When proteomics failed to identify the amyloid precursor, gene sequencing was used to identify agerelated (wild type TTR) or one of the non-TTR familial amyloidoses.
Patients with gastrointestinal symptoms without biopsy confirmation, or those who presented with initial manifestation of hepatic involvement or isolated macroglossia were excluded from analysis. 7 
Data collection
The Institutional Review Board of Boston University Medical Campus approved data collection, and written informed consent was obtained from each patient, in accordance with the Declaration of Helsinki. Gastrointestinal symptoms were recorded for each patient. Time from symptom onset to diagnosis and diagnosis to amyloid treatment and research program evaluation were determined. Other organ involvement, including cardiac, pulmonary, renal, neurologic, soft tissue, and hepatic was reviewed. For patients with AL amyloidosis, data included results of bone marrow biopsy, serum free light chain (FLC) analysis, and serum and urine immunofixation electrophoresis. The difference between the involved FLC and the uninvolved FLC (dFLC) at presentation was calculated, where applicable. Serum creatinine, B-type natriuretic peptide (BNP), serum albumin, and alkaline phosphatase levels were collected on all patients; troponin-I data were not available until June 2008, thus not all patients had this measurement available. Median overall survival and associated Kaplan-Meier survival curves were calculated for patients with systemic AL amyloidosis. In patients diagnosed with systemic AL that were never treated, charts were reviewed to confirm the diagnosis.
Follow-up was obtained on all of these patients at the time of this analysis by telephone or email.
Results
Patient characteristics
A total of 76 patients, 3% of all referred patients during the time of study, had dominant GI amyloidosis (Table 1) . Women accounted for less than half, 29 of 76 (38%). The median age at the time of diagnosis was 61 years (range, 34 -79). Sixty patients (79%) had evidence of systemic amyloidosis, while 16 patients (21%) had localized GI amyloidosis ( Figure 1 ).
Symptoms for all patients included weight loss in 33 patients (43%), gastrointestinal bleeding in 27 (36%), heartburn in 25 (33%), early satiety in 25 (33%), diarrhea in 22 (29%), and abdominal pain in 21 (28%). The median follow-up after initial evaluation was 35 months (range, 1 -159).
Systemic amyloidosis with dominant GI involvement
Of systemic patients, fifty (83%) had AL, 5 (8%) had (ALys), 3 (5%) had SSA, and 2 (3%) had mutant ATTR (Figure 1 ).
Fifty patients presented with systemic AL amyloidosis and dominant GI involvement; the median age at the time of diagnosis was 63 (range, 46 -79) (Tables 2 and 3 ). Women accounted for 18 (36%). The median time from symptoms to diagnosis was 5 months (range, 0 -220). The median time from amyloid diagnosis to evaluation was 2 months (range, 0 -80). For AL patients, the most common biopsy site leading to an amyloid diagnosis was the small bowel in 25 patients (50%) followed by stomach in 22 (44%) and colon in 16 (32%). Diagnosis during routine surveillance gastrointestinal endoscopy was made in 7 (14%); this included colorectal cancer screening and surveillance endoscopy for Barrett's esophagus. 9 Other organ involvement included neurologic in 19 (38%), cardiac in 24 (48%), and renal in 18 (36%); 50 percent of patients had more than 2 organ systems involved. Of the 7 patients with initial diagnosis made by surveillance endoscopy, 4 had more than one organ system involved; 3 of these patients had systemic amyloidosis affecting the GI tract only. Clonality of the underlying plasma cell dyscrasia was λ in 28 (56%) and κ in 22 (44%). Of the 50 patients with systemic AL, 7 (14%) had coexistent multiple myeloma and 2 (4%) had coexistent Waldenström's macroglobulinemia. The median Tn-I was 0.1 ng/mL (range 0.008 -0.423) and the median BNP was 127 pg/mL (range 7 -871). The median serum albumin was 4.1 g/dL (range, 1.7 -4.7) and median serum creatinine was 0.9 mg/dL (range, 0.41 -2.4). The median 24-hour urine total protein excretion was 225 mg (range 10 -6879). At the time of diagnosis, the median plasma cell burden on bone marrow biopsy was 10% (range, 1 -70). On patients in whom FLC analysis was available, the median involved κ FLC was 115. For the 16 patients in whom data was available, the most frequent treatment related toxicities (NCI CTCAEv3.0 Grade 1-4) included diarrhea in 9 (56%), nausea in 8 (50%), constipation in 10 (62%), GI bleeding in 4 (25%), and anorexia in 7 (44%). Only 1 patient (6%) experienced severe GI hemorrhage -defined as requiring transfusion, operative intervention, or interventional radiology. 1 patient (6%) had life threatening dehydration; no other life threatening GI toxicites were documented. The survival rate at 2 and 4 years was 84% and 72%, respectively. With a median follow-up of 25 months after evaluation, the median overall survival for patients with systemic AL amyloidosis of the GI tract was not reached (Figure 2 ).
Five patients with positive GI biopsies for amyloid were found to have ATTR amyloidosis, either mutant (2 patients) or wild-type (3 patients). The median presenting age at the time of diagnosis was 72 years (range, 42 -79). One ATTR patient had T60A, and the other had V30M .The median time from symptom onset to diagnosis was 8 months (range, 0 -27), and the median time from diagnosis to evaluation was 2 months (range, 1 -10). ATTR amyloidosis was found in the stomach in 3 patients (60%), small bowel in 2 (40%), and rectum in 1 (20%).
The most frequent presenting symptoms were early satiety in 2 patients each (40%) and weight loss in 2 (40%). The median serum albumin was 4.3 g/dL. In mutant TTR, other organ involvement included cardiac and neurologic involvement in both patients. In wild-type TTR, all 3 patients had isolated GI tract involvement, with no coexistent cardiac involvement. The two patients with mutant TTR participated in a clinical trial evaluating diflunisal in familial amyloidosis (ClinicalTrials.gov identifier NCT00294671), and one of them is currently listed for liver transplant. All three patients with wild-type ATTR were treated with supportive care only.
Five patients had ALys (7%). The median age at the time of diagnosis was 46 years (range, 36 -61). Unusually for systemic amyloid diseases, women were in the majority (4 of the 5, 80%). The median time from symptom onset to diagnosis was 1 month (range, 0 -27) and the median time from diagnosis to evaluation was 6 months (range, 2 -9). The most frequent positive biopsies were stomach in 4 (80%) and small bowel in 2 (40%). Lysozyme gene sequencing demonstrated that 4 patients, all from different pedigrees, had a W60R substitution, and 1 patient had K53N. GI bleeding and diarrhea were the presenting symptom in 3 patients (60%) and heartburn in two (40%). Isolated GI tract involvement was documented in 3 patients (60%), 1 patient had renal involvement (20%) and no patients had hepatic involvement.
Treatment for all ALys patients was supportive management and observation only, no patient is known to have undergone liver or kidney transplantation.
Localized amyloidosis of the GI tract
Sixteen patients had localized amyloidosis of the GI tract, without any evidence of an underlying plasma cell dyscrasia or other organ involvement. These patients had a normal bone marrow biopsy without evidence of clonality by immunohistochemistry or in situ hybridization, and normal serum free light chain levels and ratio. 2 patients had free lambda on SIFE, and 2 patients had free lambda on UIFE, but none had any other evidence for an underlying clonal plasma cell dyscrasia. They also lacked clinical evidence of involvement of other organs, and had no sign of amyloid deposition in a fat aspirate. Patient characteristics are summarized in Table 2 and 3. There were 6 women (38%). The median age at the time of diagnosis was 59 12 years (range, 34 -72). Serendipitous discovery on routine endoscopic surveillance screening occurred in 4 (25%). The time from symptom onset to diagnosis was 1 month (range 0 -26).
After initial diagnosis, the median time to evaluation was 4 months (range, 1 -15) . With a median follow-up after evaluation of 39 months (range, 1 -121), all 16 patients (100%) were determined to be alive; 15 out of 16 (94%) had no evidence suggestive of progression to systemic disease, while for one this information was not available.
The most frequent symptoms for localized GI patients were gastrointestinal bleeding in 8 (50%), heartburn in 8 (50%), and constipation in 3 (19). The most frequent biopsy sites were stomach in 8 (50%), colon in 7 (44%), and small bowel in 3 (19%). In 11 of the 16 cases, the amyloid type was determined using immunohistochemistry, immunoelectron microscopy, or mass spectrometry, and all of these proved to be comprised of λ light chains. Supportive care without systemic treatment was recommended for these patients.
Discussion
Of 2,334 patients evaluated at our center in a 13-year period, 76 (3.3%) were diagnosed with biopsy-proven involvement of the GI tract. For these patients, weight loss, diarrhea, and early satiety were among the most common symptoms reported, in keeping with prior reports (10, 11) . These symptoms can also occur with autonomic neuropathy due to amyloidosis, and are not diagnostic of GI involvement in the absence of biopsy-proof.
The median time from diagnosis to treatment in systemic patients was surprisingly short, only 5 months. This contrasts, for example, with a median time of 48 months for patients presenting with peripheral neuropathy (16) . Several factors might explain the more expedient time to diagnosis in patients with GI amyloidosis. The GI tract is more accessible to biopsy, so 13 endoscopy may be employed sooner in the course of the workup for symptoms. However, early diagnosis might also reflect a selection bias for those patients who are successfully diagnosed and referred. Many patients with GI amyloidosis might not have been diagnosed, if Congo red staining of biopsied material was not performed.
AL amyloidosis was the most common cause of GI amyloid involvement occurring in 50 patients as systemic disease and 11 patients with localized disease. Thus, overall, of 76 patients with biopsy-proven GI amyloidosis, 61 (80%) were due to light chain deposition. In all 11 patients with localized AL amyloidosis the amyloid deposits were caused by a λ monoclonal light chain, in keeping with prior reports of localized disease, where the majority had documented lambda light chain disease (17) . None of the patients with localized AL were found to progress to systemic disease, consistent with the hypothesis that localized AL is due to local production of light chains by a clone of plasma cells residing in the target organ (18) .
Patients with systemic AL amyloidosis were offered anti-plasma cell chemotherapy.
HDM/SCT was offered as first line therapy, as we and others have observed a high rate of hematologic complete responses (CRs) and durable remissions in patients who achieve CR; we noted an overall 6.3 year median survival and 43% CR rate in our recent update (19). However, patients with GI amyloidosis and evidence of active GI bleeding or ulceration were not offered myeloablative chemotherapy, because of the risk of catastrophic GI hemorrhage (Figures 3-4) (20). In our series we report here, severe GI bleeding occurred in only 6% of patients treated with HDM/SCT, comparable to rates of GI hemorrhage reported in other transplant series (21, 22). None of our selected patients died due to GI bleeding. Patients who were not candidates for HDM/SCT were treated on clinical trials with novel agents or with melphalan and dexamethasone. 14 Ten patients (13%) with biopsy-proven GI amyloidosis had non-AL disease. Thus, accurate typing is critical to avoid the use of chemotherapy in these patients. Of these 10 patients, 5 were due to TTR and 5 were due to ALys. Three of the five cases due to TTR were associated with SSA rather than a mutant TTR. Although wild-type TTR predominantly involves the heart, an autopsy series, from Matsutani et al, identified GI involvement in 7.8% of cases (23).
In keeping with prior reports, all of the patients with ALys amyloidosis in our series presented with symptomatic GI amyloidosis proven by biopsy. Their presentation was very similar to that described in another report (7); however, in contrast to that study, none of our patients are known to have undergone either liver or renal transplantation, and all are still alive.
Patients with GI amyloidosis require supportive care for nausea with ondansetron, granisetron, or prochlorperazine, and for diarrhea with loperamide, lomotil, or deodorized tincture of opium (2) . For dysmotility and early satiety, metoclopromide has been tried with limited success. Erythromycin, a pro-kinetic medication, has been shown to have some benefit in improving delayed gastric emptying and early satiety in an ATTR patient (24).
Five patients (31%) of the group of 16 patients with biopsy-proven GI amyloidosis without evidence for systemic disease did not have amyloid protein typing performed, due to insufficient tissue available. All 5 of these patients had a clinical course consistent with those patients who had lambda light chain localized disease, with none receiving systemic treatment, and all are still alive today. Given these findings, these patients likely have localized AL disease, despite the lack of confirmatory amyloid protein typing.
In summary, we report on a large series of 76 patients with biopsy-proven GI amyloidosis. Serendipitous biopsies appeared to play a role in the initial diagnosis of some patients with amyloidosis, and endoscopy with blind biopsies stained with Congo red should be considered for any patient with unexplained weight loss, GI bleeding, or early satiety, particularly in association with a monoclonal gammopathy or symptoms or signs of other organ disease (neuropathy, nephropathy, and cardiomyopathy). It is crucial to distinguish the type of amyloid, so patients with non-AL amyloidosis are not subjected to cytotoxic chemotherapy While systemic AL amyloidosis is the most common cause of GI amyloid involvement, only carefully selected patients with systemic AL and involvement of the GI tract can be treated safely with HDM/SCT, Localized GI amyloidosis without evidence for systemic involvement appears to be a distinct entity that, in keeping with other forms of localized amyloidosis, is due to a local population of plasma cells producing amyloidogenic immunoglobulin light chains. These patients should be monitored and treated symptomatically, but their rate of progression to systemic disease is low and their survival is excellent without systemic therapy, as none of these patients expired from their disease during the follow-up period.
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